Literature DB >> 1389935

Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

D N John1, S Fort, M J Lewis, D K Luscombe.   

Abstract

1. The pharmacokinetics and pharmacodynamics of verapamil administered via the oral and sublingual routes were compared in a randomised, two-way cross-over study involving six healthy male volunteers. 2. Administered sublingually, a verapamil 40 mg (Securon) crushed tablet produced a significantly higher peak plasma concentration (P less than 0.05), a greater rate of absorption (P less than 0.05), and greater bioavailability (P less than 0.05) when compared with orally administered verapamil 40 mg (Securon). 3. In comparison with oral dosing, PR intervals were significantly (P less than 0.05) prolonged between 30 and 90 min after sublingual verapamil dosing. 4. Correlations between log plasma verapamil concentration and percentage increase in PR interval were greater after sublingual compared with oral dosing in all volunteers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389935      PMCID: PMC1381354          DOI: 10.1111/j.1365-2125.1992.tb04091.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation.

Authors:  S M Pomfret; C R Beasley; V Challenor; S T Holgate
Journal:  Clin Sci (Lond)       Date:  1988-04       Impact factor: 6.124

2.  Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

Authors:  G Neugebauer
Journal:  Cardiovasc Res       Date:  1978-04       Impact factor: 10.787

3.  The metabolism of DL-[14C]verapamil in man.

Authors:  M Eichelbaum; M Ende; G Remberg; M Schomerus; H J Dengler
Journal:  Drug Metab Dispos       Date:  1979 May-Jun       Impact factor: 3.922

4.  Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

Authors:  R Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; G P Trevi; M Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

6.  Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter.

Authors:  J Dominic; R G McAllister; C S Kuo; C P Reddy; B Surawicz
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

7.  The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.

Authors:  J A Dominic; D W Bourne; T G Tan; E B Kirsten; R G McAllister
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jan-Feb       Impact factor: 3.105

8.  Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

Authors:  H Echizen; B Vogelgesang; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

9.  Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration.

Authors:  O P Asthana; B G Woodcock; M Wenchel; K H Frömming; L Schwabe; N Rietbrock
Journal:  Arzneimittelforschung       Date:  1984

10.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more
  5 in total

1.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

2.  Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter.

Authors:  S Fort; M J Lewis; D K Luscombe; D N John
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

Review 3.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 4.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.